|
Press Releases and Ad-hoc-Announcements 2010
June 22, 2010
|
|
MOLOGEN AG receives approval for clinical study with cell-based gene therapy against renal cancer
 the press release
the ad-hoc announcement
|
June 22, 2010
|
|
MOLOGEN AG starts phase 2 clinical study with DNA-based cancer medicine MGN1703 against colorectal cancer
the press release
|
June 11, 2010
|
|
MOLOGEN AG: Further capital increase successfully completed
the ad-hoc announcement
|
June 08, 2010
|
|
MOLOGEN AG: Efficacy of MGN1703 DNA cancer medicine far exceeds expectations
the press release
|
May 21, 2010
|
|
MOLOGEN AG presents clinical study results with MGN1703
the press release
|
May 12, 2010
|
|
MOLOGEN reaches further important milestones
the press release
|
April 06, 2010
|
|
MOLOGEN AG receives funding to develop a DNA vaccine against hepatitis B
the press release
|
March 30, 2010
|
|
MOLOGEN looks back on a very eventful and successful business year 2009
the press release
|
March 05, 2010
|
|
MOLOGEN AG receives approval for clinical study with cancer drug MGN1703
the press release
the ad-hoc announcement
|
January 08, 2010
|
|
MOLOGEN: Successful capital increase completed as planned
the press release
the ad-hoc announcement
|
|
|
NEWSLETTER |
| To subscribe to our Newsletter please
 click here
|
|
|
PRESS
RELEASES 
